A phase II study of prolonged oral etoposide in advanced or recurrent carcinoma of the cervix
| Autor: | David M. Gershenson, Kevin R. Brader, Charles F Levenback, M. Morris, Thomas W. Burke |
|---|---|
| Rok vydání: | 1998 |
| Předmět: |
Adult
medicine.medical_specialty medicine.medical_treatment Phases of clinical research Administration Oral Uterine Cervical Neoplasms Gynecologic oncology Gastroenterology Drug Administration Schedule Internal medicine Carcinoma Medicine Humans Cervix Etoposide Aged Chemotherapy business.industry Obstetrics and Gynecology Middle Aged medicine.disease Antineoplastic Agents Phytogenic Surgery medicine.anatomical_structure Prior Therapy Oncology Toxicity Female Neoplasm Recurrence Local business medicine.drug |
| Zdroj: | Gynecologic oncology. 70(2) |
| ISSN: | 0090-8258 |
| Popis: | Objective. To evaluate the efficacy and toxicity of prolonged oral etoposide as single agent chemotherapy in patients with advanced or recurrent carcinoma of the cervix. Methods. Between May 1991 and February 1993, 44 patients with advanced or recurrent carcinoma of the cervix were entered onto this study. Patients were eligible if they had received no more than two prior cytotoxic regimens. The initial dose of etoposide was 37.5 mg/m 2 administered orally on a daily basis on days 1–21 of a 28-day cycle. Subsequent doses were unchanged, reduced, escalated, or omitted according to toxicity. Patients were evaluated for response and toxicity using standard Gynecologic Oncology Group criteria. Results. Forty-four patients were evaluable for response and toxicity. The overall response rate was 9.1% (2 CR, 2 PR). In patients with no prior chemotherapy the response rate was 4/25 compared to 0/19 for those who had prior therapy. The mean response duration was 2.7 months and the median survival from treatment for all patients was 7.7 months. The major toxicity was granulocytopenia, with 11% of patients having grade 3 or 4 toxicity. Gastrointestinal toxicity of some degree occurred in 11% of patients, and alopecia was universal. Conclusion. Prolonged oral etoposide has limited activity in advanced or recurrent carcinoma of the cervix. Its use as palliative therapy for this disease is not indicated. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect